A definition and ethical evaluation of overdiagnosis

Journal of Medical Ethics

Volumn 42, Issue 11, 2016, Pages 705-714

  Carter, Stacy M ^a   Degeling, Chris ^a   Doust, Jenny ^b   Barratt, Alexandra ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BOND UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; HUMAN; HUMAN EXPERIMENT; JUSTICE; ORGANIZATION; PROFESSIONAL STANDARD;

EID: 84978870617     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2015-102928     Document Type: Article

References (49)

1. Moynihan R, Nickel B, Hersch J, et al. Public opinions about overdiagnosis: a national community survey. PLoS ONE 2015;10:e0125165.
2. Marcus PM, Prorok PC, Miller AB, et al. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst 2015;107:pii: djv014.
3. Hofmann B. Diagnosing overdiagnosis: conceptual challenges and suggested solutions. Eur J Epidemiol 2014;29:599-604.
4. Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing, 2012.
5. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 2012;344:e3502.
6. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 2015;350:g7773.
7. Welch HG, Black WC. Overdiagnosis in Cancer. J Natl Cancer Inst 2010;102:605-13.
8. Carter SM, Rogers W, Heath I, et al. The challenge of overdiagnosis begins with its definition. BMJ 2015;350:h869.
9. Hofmann B. Medicalization and overdiagnosis: different but alike. Med Health Care Philos 2016;19:253-64.
10. Welch HG, Schwartz LM, Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston: Beacon Press, 2011.
11. Aronowitz RA. The converged experience of risk and disease. Milbank Q 2009;87:417-42.
12. Rogers W, Mintzker Y. Getting clearer on overdiagnosis. J Eval Clin Pract 2016; (In Press).
13. Murphy D. Concepts of disease and health. In: Zalta EN, ed. The stanford encyclopedia of philosophy. Spring ed. http://plato.stanford.edu/archives/spr2015/entries/health-disease/2015 (accessed 26 Apr 2016).
14. Rosenberg CE. Disease in history: frames and framers. Milbank Q 1989;67:1-15.
15. Feudtner JC. Bittersweet: diabetes, insulin, and the transformation of illness. Chapel Hill: University of North Carolina Press, 2003.
16. Rock M. Classifying diabetes, or, commensurating bodies of unequal experience. Public Culture 2005;17:467-86.
17. Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013;310:797-8.
18. James JE. Personalised medicine, disease prevention, and the inverse care law: more harm than benefit? Eur J Epidemiol 2014;29:383-90.
19. Cambrosio A, Keating P, Schlich T, et al. Regulatory objectivity and the generation and management of evidence in medicine. Soc Sci Med 2006;63:189-99.
20. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in-situ-a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
21. Kaufman RH. Atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion: diagnostic criteria and management. Am J Obstet Gynecol 1996;175:1120-8.
22. Keating P, Cambrosio A. Biomedical Platforms: realigning the normal and the pathological in late twentieth-century medicine. Cambridge, MA: MIT Press, 2003.
23. Keating P, Cambrosio A. "Real compared to what?": diagnosing leukemias and lymphomas. In: Lock MM, Young A, Cambrosio A, eds. Living and working with the new medical technologies: intersections of inquiry. Cambridge: Cambridge University Press, 2000:103-33.
24. Mol A. The body multiple: ontology in medical practice. London: Duke University Press, 2002.
25. Mol A. Cutting surgeons, walking patients: some complexities involved in comparing. In: Law J, Mol A, eds. Complexities: social studies of knowledge practices. Durham: Duke University Press, 2002:218-57.
26. Moynihan R, Glasziou P, Woloshin S, et al. Winding back the harms of too much medicine. BMJ 2013;346:f1271.
27. Harris RP, Sheridan SL, Lewis CL, et al. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med 2014;174:281-6.
28. Widdows H, Cordell S. Why communities and their goods matter: illustrated with the example of biobanks. Public Health Ethics 2011;4:14-25.
29. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011;171:831-7.
30. Couteur DGL, Doust J, Creasey H, et al. Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis. BMJ 2013;347: f5125.
31. Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. BMJ 2014;349:g4485.
32. Heath I. Overdiagnosis: when good intentions meet vested interests-an essay by Iona Heath. BMJ 2013;347:f6361.
33. Tudor Hart J. The inverse care law. Lancet 1971;297:405-12.
34. Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health 2011;101:399-404.
35. Entwistle VA, Carter SM, Trevena L, et al. Communicating about screening. BMJ 2008;337:a1591.
36. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009;27:1362-7.
37. Sculpher M, Gafni A, Watt I. Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions. Soc Sci Med 2002;54:1369-77.
38. Durand MA, Carpenter L, Dolan H, et al. Do interventions designed to support shared decision-making reduce health inequalities? A systematic review and meta-analysis. PLoS ONE 2014;9:e94670.
39. Greenhalgh T, Snow R, Ryan S, et al. Six 'biases' against patients and carers in evidence-based medicine. BMC Med 2015;13:200.
40. Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA 2014;311:1403-5.
41. Yeap BB. Testosterone and cardiovascular disease risk. Curr Opin Endocrin Diabetes Obes 2015;22:193-202.
42. Singer N. Selling that new-man feeling. The New York Times. 2013 Nov 23 p.BUI1. http://www.nytimes.com/2013/11/24/business/selling-that-new-man-feeling.html (accessed 26 Apr 2016).
43. Diede SJ. Spontaneous regression of metastatic cancer: learning from neuroblastoma. Nat Rev Cancer 2014;14:71-2.
44. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med 2004;350:2010-11.
45. Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-74.
46. Bladder Cancer Clinical Guideline Update Panel. Guideline for the Management of Nonmuscle Invasive Bladder Cancer. American Urological Association, 2014. http://www.auanet.org/education/guidelines/bladder-cancer.cfm: (accessed 26 Apr 2016).
47. Carter SM. Health promotion: an ethical analysis. Health Promot J Austr 2014;25:19-24.
48. Daniels N, Sabin JE. Setting limits fairly: learning to share resources for health. 2nd edn. Oxford: Oxford University Press, 2008.
49. Degeling C, Carter SM, Rychetnik L. Which public and why deliberate? A scoping review of public deliberation in public health and health policy research. Soc Sci Med 2015;131:114-21.